(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 November 2024 (28.11.2024)

WIPO | PCT

(10) International Publication Number
WO 2024/243479 A3

(51) International Patent Classification:
A61P 29/00 (2006.01) *C07K 16/24* (2006.01)

(21) International Application Number:
PCT/US2024/030924

(22) International Filing Date:
24 May 2024 (24.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/504,051 24 May 2023 (24.05.2023) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **BEASLEY, Stephanie Lynn**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Illinois 46206-6288 (US). **GREALISH, Patrick Francis**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Illinois 46206-6288 (US). **LI, Jingxing**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Illinois 46206-6288 (US). **PAAVOLA, Chad D.**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Illinois 46206-6288 (US). **POORBAUGH, Joshua Dade**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Illinois 46206-6288 (US). **RENSCHLER, Matthew Alan**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Illinois 46206-6288 (US). **TANG, Ying**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Illinois 46206-6288 (US). **WORTINGER, Mark Andrew**; c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Illinois 46206-6288 (US).

(74) Agent: **PATEL, Dipa** et al.; Eli Lilly and Company - Patent Division, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
16 January 2025 (16.01.2025)

(54) Title: ANTIBODIES TARGETING XCL1 AND METHODS OF USING THE SAME

(57) Abstract: The present invention provides compounds and methods targeting human lymphotactins, including therapeutic antibodies, pharmaceutical compositions and methods of use thereof, useful in the field of immune-mediated diseases including ulcerative colitis, vitiligo, multiple sclerosis, alopecia areata, psoriasis, type 1 diabetes, and asthma.

WO 2024/243479 A3